Literature DB >> 25686508

Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: a population-based study.

Concetta Rafaniello1, Vincenzo Arcoraci2, Carmen Ferrajolo1, Liberata Sportiello1, Maria Giuseppa Sullo1, Francesco Giorgianni2, Gianluca Trifirò2, Michele Tari3, Achille P Caputi2, Francesco Rossi1, Katherine Esposito4, Dario Giugliano5, Annalisa Capuano6.   

Abstract

OBJECTIVE: To assess the prescribing pattern of antidiabetic drugs (AD) in a general practice of Southern Italy from 2009 to 2012, with focus on behaviour prescribing changes.
METHODS: This retrospective, drug utilization study was conducted using administrative databases of the Local Health Unit of Caserta (Southern Italy) including about 1 million citizens. The standardized prevalence of AD use was calculated within each study year. A sample cohort of 78,789 subjects with at least one prescription of AD was identified during the study period.
RESULTS: There was an overall increase of the proportion of the patients treated with monotherapy, which was significant for insulin monotherapy (from 11.2 to 14.6%, p<0.001). The proportion of patients treated with metformin remained stable (from 68.3% to 67.8%, p=0.076), while those receiving sulfonylurea dropped from 18.4% to 12.5% (p<0.001); GLP-1 analogues and DPP-4 inhibitors showed the greatest increase (from 1.2% to 6.6%, p<0.001). In the whole sample of 25,148 new AD users, metformin was the most commonly prescribed drug in monotherapy (41.9%), while insulin ranked second (13.3%).
CONCLUSION: This study shows a rising trend of AD monotherapy, with sulfonylureas and incretins showing the more negative and positive trend, respectively.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Diabetes mellitus; Medical therapy; Prescribing patterns

Mesh:

Substances:

Year:  2015        PMID: 25686508     DOI: 10.1016/j.diabres.2014.12.007

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  19 in total

1.  Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009-2015.

Authors:  Rosarita Ferrara; Valentina Ientile; Vincenzo Arcoraci; Carmen Ferrajolo; Carlo Piccinni; Andrea Fontana; Salvatore Benvenga; Gianluca Trifirò
Journal:  Endocrine       Date:  2017-02-02       Impact factor: 3.633

2.  The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy.

Authors:  Gianluca Trifirò; Fabrizio Parrino; Valeria Pizzimenti; Francesco Giorgianni; Janet Sultana; Marco Muscianisi; Chiara Troncone; Daniele U Tari; Vincenzo Arcoraci; Domenico Santoro; Giusi Russo; Viviana Lacava; Achille P Caputi
Journal:  Clin Drug Investig       Date:  2016-03       Impact factor: 2.859

3.  Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study.

Authors:  Giuseppe Roberto; Anna Girardi; Francesco Barone-Adesi; Alessandro Pecere; Valentina Ientile; Claudia Bartolini; Roberto Da Cas; Stefania Spila-Alegiani; Carmen Ferrajolo; Paolo Francesconi; Gianluca Trifirò; Elisabetta Poluzzi; Fabio Baccetti; Rosa Gini
Journal:  Front Pharmacol       Date:  2022-05-30       Impact factor: 5.988

4.  Small molecule inhibition of dipeptidyl peptidase-4 enhances bone marrow progenitor cell function and angiogenesis in diabetic wounds.

Authors:  Alexander J Whittam; Zeshaan N Maan; Dominik Duscher; Janos A Barrera; Michael S Hu; Lauren H Fischer; Sacha Khong; Sun Hyung Kwon; Victor W Wong; Graham G Walmsley; Ferdinando Giacco; Michael Januszyk; Michael Brownlee; Michael T Longaker; Geoffrey C Gurtner
Journal:  Transl Res       Date:  2018-11-02       Impact factor: 7.012

Review 5.  Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness.

Authors:  Vishal Ahuja; Chia-Hung Chou
Journal:  Curr Diab Rep       Date:  2016-06       Impact factor: 4.810

6.  Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study.

Authors:  Manel Mata-Cases; Josep Franch-Nadal; Jordi Real; Dídac Mauricio
Journal:  BMJ Open       Date:  2016-10-05       Impact factor: 2.692

7.  Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42).

Authors:  Kazuya Fujihara; Risa Igarashi; Satoshi Matsunaga; Yasuhiro Matsubayashi; Takaho Yamada; Hiroki Yokoyama; Shiro Tanaka; Hitoshi Shimano; Hiroshi Maegawa; Katsuya Yamazaki; Koichi Kawai; Hirohito Sone
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

8.  Prescription Patterns of Antidiabetic Treatment in the Elderly. Results from Southern Italy.

Authors:  Valentina Orlando; Francesca Guerriero; Daria Putignano; Valeria M Monetti; Daniele U Tari; Giuseppin Farina; Maddalena Illario; Guido Iaccarino; Enrica Menditto
Journal:  Curr Diabetes Rev       Date:  2015

9.  Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort.

Authors:  Martin Busch; Jennifer Nadal; Matthias Schmid; Katharina Paul; Stephanie Titze; Silvia Hübner; Anna Köttgen; Ulla T Schultheiss; Seema Baid-Agrawal; Johan Lorenzen; Georg Schlieper; Claudia Sommerer; Vera Krane; Robert Hilge; Jan T Kielstein; Florian Kronenberg; Christoph Wanner; Kai-Uwe Eckardt; Gunter Wolf
Journal:  BMC Nephrol       Date:  2016-06-11       Impact factor: 2.388

10.  Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey.

Authors:  Hiroki Murayama; Kota Imai; Masato Odawara
Journal:  Diabetes Ther       Date:  2018-04-25       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.